1	Rorer	NNP	2	nn
2	Group	NNP	3	nn
3	Inc.	NNP	5	nsubj
4	will	MD	5	aux
5	report	VB	40	ccomp
6	that	IN	9	complm
7	third-quarter	JJ	8	amod
8	profit	NN	9	nsubj
9	rose	VBD	5	ccomp
10	more	RBR	11	advmod
11	than	IN	12	quantmod
12	15	CD	13	num
13	%	NN	9	dobj
14	from	IN	9	prep
15	a	DT	16	det
16	year	NN	17	npadvmod
17	earlier	RBR	14	pcomp
18	,	,	9	punct
19	though	IN	24	mark
20	the	DT	21	det
21	gain	NN	24	nsubj
22	is	VBZ	24	cop
23	wholly	RB	24	advmod
24	due	JJ	9	advcl
25	to	TO	24	prep
26	asset	NN	27	nn
27	sales	NNS	25	pobj
28	,	,	40	punct
29	Robert	NNP	30	nn
30	Cawthorn	NNP	40	nsubj
31	,	,	30	punct
32	chairman	NN	30	appos
33	,	,	32	punct
34	president	NN	32	conj
35	and	CC	32	cc
36	chief	JJ	38	amod
37	executive	JJ	38	amod
38	officer	NN	32	conj
39	,	,	30	punct
40	said	VBD	0	root
41	.	.	40	punct

1	His	PRP$	2	poss
2	projection	NN	3	nsubj
3	indicates	VBZ	0	root
4	profit	NN	3	dobj
5	in	IN	4	prep
6	the	DT	8	det
7	latest	JJS	8	amod
8	quarter	NN	5	pobj
9	of	IN	4	prep
10	more	JJR	12	quantmod
11	than	IN	12	quantmod
12	$	$	9	pobj
13	17.4	CD	12	number
14	million	CD	12	number
15	,	,	12	punct
16	or	CC	12	cc
17	55	CD	18	num
18	cents	NNS	12	conj
19	a	DT	20	det
20	share	NN	18	npadvmod
21	,	,	12	punct
22	compared	VBN	12	prep
23	with	IN	22	pcomp
24	$	$	23	pobj
25	15.2	CD	24	number
26	million	CD	24	number
27	,	,	24	punct
28	or	CC	24	cc
29	48	CD	30	num
30	cents	NNS	24	conj
31	a	DT	32	det
32	share	NN	30	npadvmod
33	,	,	24	punct
34	a	DT	35	det
35	year	NN	36	npadvmod
36	ago	RB	24	advmod
37	.	.	3	punct

1	Mr.	NNP	2	nn
2	Cawthorn	NNP	3	nsubj
3	said	VBD	0	root
4	in	IN	3	prep
5	an	DT	6	det
6	interview	NN	4	pobj
7	that	IN	10	complm
8	sales	NNS	10	nsubj
9	will	MD	10	aux
10	show	VB	3	ccomp
11	an	DT	12	det
12	increase	NN	10	dobj
13	from	IN	12	prep
14	a	DT	15	det
15	year	NN	16	npadvmod
16	ago	RB	13	pcomp
17	of	IN	12	prep
18	``	``	17	punct
19	somewhat	RB	22	quantmod
20	less	JJR	22	quantmod
21	than	IN	22	quantmod
22	10	CD	23	num
23	%	NN	17	pobj
24	.	.	3	punct
25	''	''	3	punct

1	Through	IN	11	prep
2	the	DT	5	det
3	first	JJ	5	amod
4	six	CD	5	num
5	months	NNS	1	pobj
6	of	IN	5	prep
7	1989	CD	6	pobj
8	,	,	11	punct
9	sales	NNS	11	nsubj
10	had	VBD	11	aux
11	grown	VBN	0	root
12	about	RB	13	quantmod
13	12	CD	14	num
14	%	NN	11	dobj
15	from	IN	11	prep
16	the	DT	18	det
17	year-earlier	JJ	18	amod
18	period	NN	15	pobj
19	.	.	11	punct

1	Growth	NN	6	nsubj
2	of	IN	1	prep
3	10	CD	4	num
4	%	NN	2	pobj
5	would	MD	6	aux
6	make	VB	0	root
7	sales	NNS	12	nsubj
8	for	IN	7	prep
9	the	DT	11	det
10	latest	JJS	11	amod
11	quarter	NN	8	pobj
12	$	$	6	xcomp
13	269	CD	12	number
14	million	CD	12	number
15	,	,	12	punct
16	compared	VBN	12	prep
17	with	IN	16	pcomp
18	$	$	17	pobj
19	244.6	CD	20	number
20	million	CD	18	num
21	a	DT	22	det
22	year	NN	23	npadvmod
23	ago	RB	18	advmod
24	.	.	6	punct

1	Mr.	NNP	2	nn
2	Cawthorn	NNP	3	nsubj
3	said	VBD	0	root
4	the	DT	6	det
5	profit	NN	6	nn
6	growth	NN	12	nsubj
7	in	IN	6	prep
8	the	DT	10	det
9	latest	JJS	10	amod
10	quarter	NN	7	pobj
11	was	VBD	12	cop
12	due	JJ	3	ccomp
13	to	TO	12	prep
14	the	DT	15	det
15	sale	NN	13	pobj
16	of	IN	15	prep
17	two	CD	19	num
18	Rorer	NNP	19	nn
19	drugs	NNS	16	pobj
20	.	.	3	punct

1	Asilone	NNP	7	nsubjpass
2	,	,	1	punct
3	an	DT	4	det
4	antacid	NN	1	appos
5	,	,	1	punct
6	was	VBD	7	auxpass
7	sold	VBN	0	root
8	to	TO	7	prep
9	Boots	NNP	10	nn
10	PLC	NNP	8	pobj
11	,	,	10	punct
12	London	NNP	10	appos
13	.	.	7	punct

1	Thrombinar	NNP	11	nsubjpass
2	,	,	1	punct
3	a	DT	4	det
4	drug	NN	1	appos
5	used	VBN	4	partmod
6	to	TO	7	aux
7	stanch	VB	5	xcomp
8	bleeding	NN	7	dobj
9	,	,	1	punct
10	was	VBD	11	auxpass
11	sold	VBN	0	root
12	to	TO	11	prep
13	Jones	NNP	15	nn
14	Medical	NNP	15	nn
15	Industries	NNP	16	nn
16	Inc.	NNP	12	pobj
17	,	,	16	punct
18	St.	NNP	19	nn
19	Louis	NNP	16	appos
20	.	.	11	punct

1	He	PRP	2	nsubj
2	said	VBD	0	root
3	Rorer	NNP	4	nsubj
4	sold	VBD	2	ccomp
5	the	DT	6	det
6	drugs	NNS	4	dobj
7	for	IN	4	prep
8	``	``	7	punct
9	nice	JJ	10	amod
10	prices	NNS	7	pobj
11	''	''	7	punct
12	and	CC	4	cc
13	will	MD	14	aux
14	record	VB	4	conj
15	a	DT	19	det
16	combined	VBN	19	amod
17	,	,	19	punct
18	pretax	JJ	19	amod
19	gain	NN	14	dobj
20	on	IN	19	prep
21	the	DT	22	det
22	sales	NNS	20	pobj
23	of	IN	19	prep
24	$	$	23	pobj
25	20	CD	24	number
26	million	CD	24	number
27	.	.	2	punct

1	As	IN	7	mark
2	the	DT	3	det
3	gain	NN	7	nsubj
4	from	IN	3	prep
5	the	DT	6	det
6	sales	NNS	4	pobj
7	indicates	VBZ	11	advcl
8	,	,	11	punct
9	operating	NN	10	nn
10	profit	NN	11	nsubj
11	was	VBD	22	ccomp
12	``	``	15	punct
13	significantly	RB	15	advmod
14	''	''	15	punct
15	below	IN	11	prep
16	the	DT	18	det
17	year-earlier	JJ	18	amod
18	level	NN	15	pobj
19	,	,	22	punct
20	Mr.	NNP	21	nn
21	Cawthorn	NNP	22	nsubj
22	said	VBD	0	root
23	.	.	22	punct

1	Rorer	NNP	5	nsubj
2	in	IN	5	prep
3	July	NNP	2	pobj
4	had	VBD	5	aux
5	projected	VBN	0	root
6	lower	JJR	9	amod
7	third-quarter	JJ	9	amod
8	operating	NN	9	nn
9	profit	NN	5	dobj
10	but	CC	9	cc
11	higher	JJR	12	amod
12	profit	NN	9	conj
13	for	IN	12	prep
14	all	DT	13	pobj
15	of	IN	14	prep
16	1989	CD	15	pobj
17	.	.	5	punct

1	He	PRP	2	nsubj
2	said	VBD	0	root
3	the	DT	4	det
4	company	NN	7	nsubj
5	is	VBZ	7	aux
6	still	RB	7	advmod
7	looking	VBG	2	ccomp
8	for	IN	7	prep
9	``	``	8	punct
10	a	DT	13	det
11	strong	JJ	13	amod
12	fourth	JJ	13	amod
13	quarter	NN	8	pobj
14	in	IN	13	prep
15	all	DT	16	det
16	areas	NNS	14	pobj
17	--	:	16	punct
18	sales	NNS	16	dep
19	,	,	18	punct
20	operating	NN	21	nn
21	income	NN	18	conj
22	and	CC	18	cc
23	net	JJ	24	amod
24	income	NN	18	conj
25	.	.	2	punct
26	''	''	2	punct

1	Mr.	NNP	2	nn
2	Cawthorn	NNP	3	nsubj
3	attributed	VBD	0	root
4	the	DT	5	det
5	decline	NN	3	dobj
6	in	IN	5	prep
7	third-quarter	JJ	9	amod
8	operating	NN	9	nn
9	profit	NN	6	pobj
10	to	TO	3	prep
11	the	DT	13	det
12	stronger	JJR	13	amod
13	dollar	NN	10	pobj
14	,	,	13	punct
15	which	WDT	16	nsubj
16	reduces	VBZ	13	rcmod
17	the	DT	18	det
18	value	NN	16	dobj
19	of	IN	18	prep
20	overseas	JJ	21	amod
21	profit	NN	19	pobj
22	when	WRB	25	advmod
23	it	PRP	25	nsubjpass
24	is	VBZ	25	auxpass
25	translated	VBN	18	dep
26	into	IN	25	prep
27	dollars	NNS	26	pobj
28	;	:	10	punct
29	to	TO	10	conj
30	accelerated	VBN	31	amod
31	buying	NN	29	pobj
32	of	IN	31	prep
33	Rorer	NNP	34	nn
34	products	NNS	32	pobj
35	in	IN	31	prep
36	the	DT	38	det
37	second	JJ	38	amod
38	quarter	NN	35	pobj
39	because	IN	40	mwe
40	of	IN	31	prep
41	a	DT	46	det
42	then-pending	JJ	46	amod
43	July	NNP	46	dep
44	1	CD	43	dep
45	price	NN	46	nn
46	increase	NN	40	pobj
47	,	,	10	punct
48	and	CC	10	cc
49	to	TO	10	conj
50	higher	JJR	52	amod
51	marketing	NN	52	nn
52	expenses	NNS	49	pobj
53	for	IN	52	prep
54	Rorer	NNP	57	poss
55	's	POS	54	possessive
56	Maalox	NNP	57	nn
57	antacid	NN	53	pobj
58	,	,	57	punct
59	whose	WP$	63	poss
60	sales	NNS	63	nn
61	and	CC	63	cc
62	market	NN	63	conj
63	share	NN	68	nsubj
64	in	IN	63	prep
65	the	DT	66	det
66	U.S.	NNP	64	pobj
67	had	VBD	68	aux
68	slipped	VBN	57	rcmod
69	in	IN	68	prep
70	the	DT	72	det
71	first	JJ	72	amod
72	half	NN	69	pobj
73	of	IN	72	prep
74	1989	CD	73	pobj
75	.	.	3	punct

1	He	PRP	2	nsubj
2	said	VBD	0	root
3	Rorer	NNP	4	nsubj
4	opted	VBD	2	ccomp
5	to	TO	6	aux
6	sell	VB	4	xcomp
7	Asilone	NNP	6	dobj
8	and	CC	7	cc
9	Thrombinar	NNP	7	conj
10	to	TO	11	aux
11	raise	VB	6	xcomp
12	revenue	NN	11	dobj
13	that	WDT	17	nsubj
14	would	MD	17	aux
15	``	``	17	punct
16	kick	NN	17	dep
17	start	VB	12	rcmod
18	''	''	17	punct
19	its	PRP$	22	poss
20	increased	VBN	22	amod
21	marketing	NN	22	nn
22	efforts	NNS	17	dobj
23	behind	IN	22	prep
24	Maalox	NNP	23	pobj
25	,	,	24	punct
26	still	RB	24	advmod
27	its	PRP$	29	poss
28	top-selling	JJ	29	amod
29	product	NN	24	dep
30	with	IN	24	prep
31	about	RB	32	quantmod
32	$	$	30	pobj
33	215	CD	32	number
34	million	CD	32	number
35	in	IN	32	prep
36	world-wide	JJ	37	amod
37	sales	NNS	35	pobj
38	in	IN	32	prep
39	1988	CD	38	pobj
40	.	.	2	punct

1	``	``	4	punct
2	We	PRP	4	nsubj
3	had	VBD	4	aux
4	underfunded	VBN	0	root
5	Maalox	NNP	4	dobj
6	for	IN	4	prep
7	a	DT	8	det
8	year	NN	6	pobj
9	,	,	12	punct
10	''	''	12	punct
11	he	PRP	12	nsubj
12	said	VBD	4	parataxis
13	,	,	12	punct
14	because	IN	18	mark
15	the	DT	16	det
16	company	NN	18	nsubj
17	was	VBD	18	aux
18	concentrating	VBG	4	advcl
19	on	IN	18	prep
20	research	NN	19	pobj
21	and	CC	20	cc
22	development	NN	20	conj
23	and	CC	20	cc
24	promoting	VBG	20	conj
25	other	JJ	26	amod
26	drugs	NNS	24	dobj
27	.	.	4	punct

1	He	PRP	2	nsubj
2	said	VBD	0	root
3	Rorer	NNP	5	nsubj
4	will	MD	5	aux
5	spend	VB	2	ccomp
6	$	$	10	dep
7	15	CD	10	number
8	million	CD	10	number
9	to	TO	10	dep
10	$	$	13	num
11	20	CD	10	number
12	million	CD	10	number
13	more	JJR	5	dobj
14	on	IN	5	prep
15	Maalox	NNP	16	nn
16	advertising	NN	14	pobj
17	and	CC	16	cc
18	promotion	NN	16	conj
19	in	IN	16	prep
20	the	DT	22	det
21	second	JJ	22	amod
22	half	NN	19	pobj
23	of	IN	22	prep
24	1989	CD	23	pobj
25	than	IN	5	prep
26	in	IN	25	pcomp
27	the	DT	29	det
28	year-earlier	JJ	29	amod
29	period	NN	26	pobj
30	.	.	2	punct

1	A	DT	4	det
2	``	``	4	punct
3	big	JJ	4	amod
4	chunk	NN	10	nsubj
5	''	''	4	punct
6	of	IN	4	prep
7	that	DT	9	det
8	additional	JJ	9	amod
9	spending	NN	6	pobj
10	came	VBD	17	ccomp
11	in	IN	10	prep
12	the	DT	14	det
13	third	JJ	14	amod
14	quarter	NN	11	pobj
15	,	,	17	punct
16	he	PRP	17	nsubj
17	said	VBD	0	root
18	.	.	17	punct


